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Summary: Neopterin concentrations increase in serum and urine within the first week of infection with HIV
and remain increased throughout the infection. In particular, changes in neopterin concentration precede
decreases in CD4 T cell numbers and the development of clinical disease, and they can be used to predict the
later development of AIDS. The increased neopterin concentrations show that the immune system is activated
in HIV infection and demonstrate the presence of an interaction between the virus and the immune system.
The most important future use of neopterin measurements may be in fast evaluation of new drugs in HIV
infection.
Introduction and Background
The average of ten years between infection and de-
velopment of AIDS distinguishes infection with HIV
from most other infections. Many HIV-induced
changes, however, can be detected in the immune
system during these ten years of latent infection. Cer-
tain immune changes correlate with the time for the
later development of AIDS, and are therefore related
to the underlying pathological process of the disease.
Many of the changes are established immediately after
HIV seroconversion and remained detectable
throughout the disease. The serum concentration of
neopterin is such an immünological quantity. Neo-
pterin is a marker for infectious diseases, especially
viral diseases involving the macrophage system.
Production of neopterin
Neopterin is produced in response to immune acti-
vation. Many medical conditions in which immune
activation is a part of the disease have high serum
concentrations of neopterin. Such conditions are al-
logeneic graft rejections, autoimmune diseases, infec-
tious diseases, and after immunostimulatory treat-
ment with interferon gamma or interleukin-2 (1). Ex-
tensive work has shown that macrophages are the
primary neopterin-producing cells, which release
neopterin in response to interferon gamma (2, 3).
Under different in vitro conditions, B cells also release
neopterin in response to either interferon gamma or
interleukin-2 by an unknown mechanism (4, 5). Neo-
pterin can be measured in either serum or in urine
and the two measurements correlate well (6). Meas-
urements of neopterin in urine are particularly useful
when frequent measurements are required in infants.
Neopterin is quantitated by two different methods.
One is a radioimmune assay using radioactively la-
belled neopterin and a monoclonal antibody against
neopterin (7). The other is high performance liquid
chromatography separation and quantitation by com-
parison with samples containing known amounts of
neopterin (8). Both methods have pitfalls, especially
in the collection and storage of samples. Although
neopterin is rather stable, light, high temperatures or
repeated thawing and freezing may interfere with
quantitation. For urine samples, the most reliable
results are obtained when neopterin is measured in
spontaneous early urine and related to the simulta-
neously measured urine creatinine concentration.
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Immune act ivat ion in HIV infection
Late in the course of infection with HIV, paralysis of
the cellular immune function (9, 10) as well as im-
pairment of the ability to replenish the CD4 T cells
lead to development of AIDS. The impairment of
immune function, however, seems to go hand in hand
with the general immune activation. Wächter, Fuchs
and colleagues showed as early as 1983 that serum
concentrations of neopterin were strongly increased
in patients with AIDS (11, 12). With the knowledge
available then it was very difficult to imagine how
immune activation and deficiency could occur simul-
taneously. To day, it is well known that immune
activation can lead to either an immune response or
anergy (13), and the two concepts are no longer con-
tradictory. In retrospect, before HIV was discovered,
many researchers believed that AIDS was due to a
generalized immune activation resulting in an ex-
haustion of the immune system. This concept was
based on the finding of increased concentrations of
CDS T cells in the peripheral blood (14) and the
polyclonal activation of B cells resulting in increased
concentrations of immunoglobulin (15).
Unfortunately, for several years the focus was shifted
totally toward the newly discovered HIV virus. In
1989, an article by Fahey et al. again draw the atten-
tion toward immune activation in HIV infection (16).
By testing samples from the large multicenter AIDS
cohort study (MACS) in Los Angeles and applying
survival statistics, the article showed that the concen-
trations of various serum activation markers, alone
or in combination, were highly predictive for the
development AIDS in HIV-seropositive subjects.
Other articles showed that neopterin concentrations
in serum measured at an average time of three months
after HIV seroconversion also were predictive for the
decline in CD4 T cell numbers after four and five
years infection (17). Although the latter study showed
that neopterin serum concentrations have the strong-
est predictive power, other serum activation markers
such as ß2-microglobulin, soluble interleukin-2 recep-
tors and soluble CDS have been shown to have similar
properties (18-20). In most risk groups, a strong
correlation between neopterin and ß2-microglobulin
concentrations in serum indicates that the patholog-
ical mechanism responsible for the increase in these
markers is the same. In contrast, soluble interleukin-2
receptor concentrations do not correlate with neo-
pterin concentrations and, therefore, seem to be
driven by a separate mechanism. Neopterin concen-
trations also correlate with phenotypic cellular acti-
vation markers such as HLA-DR, CD8/38 and CDS/
CD45RA (21).
Mechanism behind the neopterin production
in HIV infection
The mechanism by which HIV infection induces im-
mune activation is unknown, although we have earlier
shown that HIV proteins are able to induce neopterin
production in normal peripheral blood inononuclear
cells in vitro (unpublished, Hofmann, Nishanian,
Fahey). The neopterin production both in vitro and
in vivo is most likely secondary to induction of inter-
feron gamma production. Increased serum concentra-
tions of interferon gamma have been found in HIV-
seropositive subjects (22) and could as such explain
the neopterin production by inducing activation of
macrophages and perhaps B cells. That macrophages
are activated in HIV infection has been demonstrated
by showing increased serum concentrations of mac-
rophage-derived interleukin-6 (23). Other evidence for
a relationship between neopterin production and the
viral infection is that serum neopterin concentrations
correlate with the in vitro replicative capacity of
HIV-1 isolates (24). The relationship to the cellular
immune deficiency is indicated by the relationship
between neopterin concentrations and the decreased
in vitro ability of T cells from HIV-seropositive sub-
jects to produce interleukin-2 (25).
Neopterin Concentrations in Different Stages
of HIV Infection
HIV seroconversion and symptomatic
primary infection
Serum neopterin concentrations increase early after
infection with HIV. Gaines et al. (26) showed highly
increased neopterin serum concentrations in 4/4 in-
dividuals tested within the first few days of primary
HIV infection. These data are similar to those ob-
tained in rhesus macaques after experimental infection
with SIV showing increased neopterin concentrations
within the first two weeks of infection (27). Similar
findings are likely in non-symptomatic individuals,
since Melmed et al. (17) showed an increased neo-
pterin concentration in 29/29 individuals tested at an
average time of three months after HIV seroconver-
sion. The increase in neopterin concentration is not
specific for HIV but is an early marker for an ongoing
viral infection.
Asymptomatic disease
The highest average serum iisopterin concentrations
are found about one year after HIV seroconversion,
whereafter the concentration dicreases to an average
concentration that remains about twice the pre-sero*
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conversion concentration (17). This concentration,
however, varies from individual to individual. Thus,
those with the fastest decline in CD4 T cell numbers
have the highest neopterin concentrations, whereas
those with stable CD4 T cell numbers have the lowest
concentrations (17).
HIV-related symptoms and AIDS
Cross sectional studies of HIV-seropositive subjects
showed progressively increasing mean concentrations
of neopterin in the order: asymptomatic HIV sero-
positive individuals < patients with AIDS-related
symptoms but with AIDS (ARC) < AIDS patients
with the highest neopterin concentrations (28, 29).
Neopterin as a prognostic marker
for development of AIDS
The clinical relevance of neopterin concentrations is
the power to predict later development of AIDS and
death. Several studies have shown that high concen-
trations of serum neopterin correlate with early AIDS
development, whereas low concentrations are associ-
ated with a disease-free interval of several years (16,
17, 29 — 32). Neopterin concentrations provide prog-
nostic information in most studies almost or as strong
as the CD4 T cell numbers. Since neopterin concen-
trations and CD4 T cell numbers do not strongly
correlate, neopterin concentrations provide prognos-
tic information in addition to CD4 T cell numbers,
and the two quantities together give a stronger pre-
diction of the time for development of AIDS than
either one of them alone (16, 30—33).
Neopterin in different risk groups of
HIV-infected individuals
Although the association between increased neopterin
and HIV infection was first established in homosexual
men other risk groups have also been extensively
studied, such as haemophiliacs (34—36), i.v. drug
users (33, 37) and Africans (38, 39). Other infections
than HIV can also lead to increased neopterin con-
centrations, which can complicate the interpretation
in, for example, patients from Africa (40). In i. v. drug
users, only hepatitis, and not the frequent bacterial
infections, leads to increased neopterin concentrations
(41). The bacterial infections, however, may interfere
with other activation markers, since the ß2-micro-
globulin concentrations, which usually are strongly
correlated with neopterin concentrations, do not have
prognostic value in i, v. drug users (33).
Neopterin concentrations have a special implication
in HIV-infected infants, because the physiologically
high CD4 T cell numbers in infants reduce the use-
fulness of this quantity. Although maternal neopterin
concentrations do not predict maternal transmission
(42), neopterin concentrations are increased in HIV-
infected infants. When other infections are excluded,
high neopterin concentrations in infants and older
children correlate with disease severity and are pre-
dictive of disease progression (43—45).
Neopterin as a marker in neurological HIV
disease
Neopterin concentrations do not distinguish between
different clinical manifestations of HIV-induced dis-
eases. In neurological HIV disease, however, direct
measurements of neopterin in cerebrospinal fluid have
been shown to correlate with the degree of neurolog-
ical involvement (46—47). The concentrations of
neopterin in cerebrospinal fluid in individuals with
neurological HIV disease are increased above the se-
rum and urine concentrations (46).
Neopterin as a marker for the effect
of antiviral treatment in HIV infection
Because of the prolonged course of the disease, sur-
vival analysis is not of great value in the evaluation
of the effect of new antiviral treatments. The effect
of the treatment on paraclinical quantities associated
with the disease pathology (such as neopterin, ß2-
microglobulin and CD4 T cell numbers) has, there-
fore, been evaluated. While the increase in CD4 T cell
numbers is small in response to treatment with zido-
vudine, this drug decreases the immune activation, as
indicated by the decrease in neopterin, which can be
detected within the first week of treatment (49). Also,
the ß2-microglobulin concentration decreases, but the
two markers respond differently, neopterin concen-
trations remaining below baseline during treatment,
while ß2-microglobulin concentrations return to nor-
mal within half a year (50, 51). The significance of
this is unknown.
Conclusions
The strong correlation between neopterin concentra-
tions and HIV disease progression/activity has estab-
lished neopterin as an important marker of the disease
pathology. Further, neopterin meaurements have di-
rected attention away from the viral infection alone
and back to the interaction between the immune sys-
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tern and the virus. The ability to measure neopterin
in urine makes it an easily accessible marker. In future,
neopterin may have particular importance in evalu-
ating new drugs for the treatment of HIV infections.
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